Warning! GuruFocus detected
1 Severe warning sign
with GRCE.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Grace Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : CA00430K4028
Share Class Description:
GRCE: Ordinary SharesDescription
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.85 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 27.3 | |||||
| 3-Year EPS without NRI Growth Rate | 34.7 | |||||
| 3-Year FCF Growth Rate | 34.2 | |||||
| 3-Year Book Growth Rate | -20 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.83 | |||||
| 9-Day RSI | 32.2 | |||||
| 14-Day RSI | 34.11 | |||||
| 3-1 Month Momentum % | -18.6 | |||||
| 6-1 Month Momentum % | -3.21 | |||||
| 12-1 Month Momentum % | -11.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.06 | |||||
| Quick Ratio | 6.06 | |||||
| Cash Ratio | 5.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -22.73 | |||||
| ROA % | -19.33 | |||||
| ROIC % | -27.65 | |||||
| 3-Year ROIIC % | 1.56 | |||||
| ROC (Joel Greenblatt) % | -68692.62 | |||||
| ROCE % | -25.01 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.44 | |||||
| Price-to-Tangible-Book | 8.11 | |||||
| EV-to-EBIT | -0.6 | |||||
| EV-to-EBITDA | -0.6 | |||||
| EV-to-FCF | -0.72 | |||||
| Price-to-Net-Current-Asset-Value | 8.11 | |||||
| Price-to-Net-Cash | 11.95 | |||||
| Earnings Yield (Greenblatt) % | -166.67 | |||||
| FCF Yield % | -45.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GRCE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Grace Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.54 | ||
| Beta | 0.84 | ||
| 3-Year Sharpe Ratio | -0.2 | ||
| 3-Year Sortino Ratio | -0.31 | ||
| Volatility % | 34.49 | ||
| 14-Day RSI | 34.11 | ||
| 14-Day ATR ($) | 0.218948 | ||
| 20-Day SMA ($) | 2.5037 | ||
| 12-1 Month Momentum % | -11.18 | ||
| 52-Week Range ($) | 2.07 - 4.965 | ||
| Shares Outstanding (Mil) | 13.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Grace Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Grace Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Grace Therapeutics Inc Frequently Asked Questions
What is Grace Therapeutics Inc(GRCE)'s stock price today?
The current price of GRCE is $2.27. The 52 week high of GRCE is $4.97 and 52 week low is $2.07.
When is next earnings date of Grace Therapeutics Inc(GRCE)?
The next earnings date of Grace Therapeutics Inc(GRCE) is 2025-06-20 Est..
Does Grace Therapeutics Inc(GRCE) pay dividends? If so, how much?
Grace Therapeutics Inc(GRCE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers